Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by ZigZagon Apr 05, 2018 1:36pm
144 Views
Post# 27837252

Who among MDR patients don't want to save his life rapidly?

Who among MDR patients don't want to save his life rapidly?

I am not really an expert in HIV & MDR patients but it seems to me that the pool of 20,000 to 25,000 patients represents people who are sick to the point of dying in the coming months or in the next 1 to 2 years. We are anticipating here sales for the first year, depending on who speaks, between 500 and 10000 patients, with an average of 4000 patients. But why such a low adoption rate? You seem to forget that these people do not have the time to wait and risk dying while waiting. Who among them would be crazy enough not to make a request to their doctor to get the Trogarzo in the first few months when it will be available? Considering this, I can not understand that the rate of adoption of the drug is less than 80% of the pool of eligible patients, in the first 6 to 12 months after the Trogarzo is put on sale ... That would represents 16000+ to 20000+ patients.  What that I do not understand?

I am a shareholder of TH since 2001.
And i read this board since 2015.

Bullboard Posts